Ester Lozano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5414622/publications.pdf

Version: 2024-02-01

44 2,656 23
papers citations h-index

45 45 45 3989 all docs docs citations times ranked citing authors

330143

37

g-index

#	Article	IF	Citations
1	Multicentric Standardization of Protocols for the Diagnosis of Human Mitochondrial Respiratory Chain Defects. Antioxidants, 2022, 11, 741.	5.1	4
2	Two Novel Variants in YARS2 Gene Are Responsible for an Extended MLASA Phenotype with Pancreatic Insufficiency. Journal of Clinical Medicine, 2021, 10, 3471.	2.4	4
3	Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. Frontiers in Immunology, 2021, 12, 792609.	4.8	3
4	Mitochondrial Toxicogenomics for Antiretroviral Management: HIV Post-exposure Prophylaxis in Uninfected Patients. Frontiers in Genetics, 2020, 11, 497.	2.3	13
5	Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 4688-4698.	7.0	30
6	The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. PLoS ONE, 2020, 15, e0241778.	2.5	5
7	Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor., 2019, 7, 259.		10
8	Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia, 2018, 32, 1427-1434.	7.2	48
9	Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma. Journal of Immunology, 2018, 200, 2581-2591.	0.8	19
10	Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways. Frontiers in Immunology, 2018, 9, 809.	4.8	33
11	Mir-485-3p and Mir-654-3p Expression in Bone Marrow Mesenchymal Stromal Cells in Patients with Monoclonal Gammopathies Is Related to the Status of the Disease. Blood, 2018, 132, 3155-3155.	1.4	O
12	Smoldering Multiple Myeloma: Usefulness of Serum Heavy/Light Chain Measurements for the Evaluation of Evolving Pattern. Blood, 2018, 132, 4514-4514.	1.4	0
13	Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2017, 23, 1269-1275.	2.0	3
14	Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis. Annals of the Rheumatic Diseases, 2017, 76, 1624-1634.	0.9	67
15	Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 238-245.	3.0	5
16	The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in <i>in vitro</i> and <i>in vivo</i> models of multiple myeloma by blockade of Ikaros and MYC signaling. Haematologica, 2017, 102, 1776-1784.	3.5	43
17	Influence of Mitochondrial Genetics on the Mitochondrial Toxicity of Linezolid in Blood Cells and Skin Nerve Fibers. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	33
18	Prevalence and prognosis implication of <i>MYD88</i> L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia. British Journal of Haematology, 2017, 179, 849-851.	2.5	11

#	Article	IF	CITATIONS
19	Blocking interferon \hat{I}^3 reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis. Annals of the Rheumatic Diseases, 2016, 75, 1177-1186.	0.9	89
20	Natural Killer Cells Transfer Antimicrobial and Antitumoral Histone H2AZ to Kill Multiple Myeloma Cells Contributing to Transmissible Cytotoxicity. Blood, 2016, 128, 2115-2115.	1.4	1
21	BET Bromodomain Blockade Enhances Ikaros Inhibition By Lenalidomide Therapy Providing Additional Activity in In Vitro and In Vivo Models of Multiple Myeloma. Blood, 2016, 128, 308-308.	1.4	0
22	Characterization of TCR repertoire of CD4+ and CD8+ T cells from patients with multiple myeloma in sustained complete remission. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e226-e227.	0.4	0
23	BET bromodomain blockade enhances Ikaros inhibition by lenalidomide therapy providing additional activity in in vitro and in vivo models of multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e229-e230.	0.4	1
24	Long-Term Survivors after Stem Cell Transplantation in Multiple Myeloma: Bone Marrow Minimal Residual Disease, PET/CT and Immunological Status. Blood, 2015, 126, 4192-4192.	1.4	0
25	Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses. Immunity, 2014, 40, 569-581.	14.3	702
26	Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis. Annals of the Rheumatic Diseases, 2014, 73, 616-623.	0.9	68
27	The CD226/CD155 Interaction Regulates the Proinflammatory (Th1/Th17)/Anti-Inflammatory (Th2) Balance in Humans. Journal of Immunology, 2013, 191, 3673-3680.	0.8	89
28	Functionally Relevant Treg Cells Are Present in Giant Cell Arteritis Lesions: Comment on the Article by Samson et al. Arthritis and Rheumatism, 2013, 65, 1133-1134.	6.7	1
29	Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Annals of the Rheumatic Diseases, 2013, 72, 1481-1487.	0.9	96
30	The TIGIT/CD226 Axis Regulates Human T Cell Function. Journal of Immunology, 2012, 188, 3869-3875.	0.8	393
31	Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis-a prospective longitudinal study. Rheumatology, 2011, 50, 2061-2070.	1.9	97
32	Interleukin-9 Secretion by Human Th17 Cells is Inducible by TGF- \hat{l}^2 and Proinflammatory Cytokines and is Increased in Autoimmune Diabetes. Clinical Immunology, 2010, 135, S29.	3.2	0
33	Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor \hat{l}_{\pm} and) Tj ETQq1 1 0.78431 Research, 2010, 62, 835-841.	.4 rgBT /C 3.4	verlock 10 1 75
34	Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events. Annals of the Rheumatic Diseases, 2010, 69, 434-442.	0.9	59
35	TGF-Î ² Induces IL-9 Production from Human Th17 Cells. Journal of Immunology, 2010, 185, 46-54.	0.8	152
36	Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. Haematologica, 2010, 95, 456-463.	3.5	16

#	Article	IF	CITATIONS
37	The spectrum of vascular involvement in giantâ€eell arteritis: clinical consequences of detrimental vascular remodelling at different sites. Apmis, 2009, 117, 10-20.	2.0	44
38	Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: A crossâ€sectional screening of fiftyâ€four prospectively followed patients. Arthritis and Rheumatism, 2008, 59, 422-430.	6.7	174
39	Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine, 2008, 41, 244-253.	3.2	41
40	Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. Annals of the Rheumatic Diseases, 2008, 67, 1581-1588.	0.9	71
41	Gelatinase expression and proteolytic activity in giant-cell arteritis. Annals of the Rheumatic Diseases, 2007, 66, 1429-1435.	0.9	76
42	Five Clinical Conundrums in the Management of Giant Cell Arteritis. Rheumatic Disease Clinics of North America, 2007, 33, 819-834.	1.9	26
43	Stimulatory Autoantibodies to the PDGF Receptor in Scleroderma. New England Journal of Medicine, 2006, 355, 1278-1280.	27.0	8
44	Dual function of focal adhesion kinase in regulating integrinâ€induced MMPâ€⊋ and MMPâ€9 release by human T lymphoid cells. FASEB Journal, 2005, 19, 1875-1877.	0.5	46